Fidelity Select Pharmaceuticals Portfolio (FPHAX)
NASDAQ · Mutual Fund
· Delayed Price · Currency is USD
22.79
-0.18 (-0.78%)
May 9, 2025, 8:04 PM EDT
Fund Assets | 1.16B |
Expense Ratio | 0.67% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 1.12 |
Dividend Yield | 4.78% |
Dividend Growth | 1.46% |
Payout Frequency | Semi-Annual |
Ex-Dividend Date | Apr 11, 2025 |
Previous Close | 22.97 |
YTD Return | -9.42% |
1-Year Return | -16.72% |
5-Year Return | 35.99% |
52-Week Low | 22.01 |
52-Week High | 31.58 |
Beta (5Y) | 0.57 |
Holdings | 60 |
Inception Date | Jun 18, 2001 |
About FPHAX
The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
Fund Family Fidelity
Category Health
Stock Exchange NASDAQ
Ticker Symbol FPHAX
Index S&P 500 TR
Performance
FPHAX had a total return of -16.72% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.90%.
Top 10 Holdings
76.87% of assetsName | Symbol | Weight |
---|---|---|
Eli Lilly and Company | LLY | 24.89% |
Novo Nordisk A/S | NVO | 12.25% |
AstraZeneca PLC | AZN | 10.29% |
GSK plc | GSK | 5.63% |
Gilead Sciences, Inc. | GILD | 5.44% |
Merck & Co., Inc. | MRK | 5.29% |
UCB SA | UCB | 4.87% |
Royalty Pharma plc | RPRX | 2.98% |
Fidelity Cash Central Fund | n/a | 2.90% |
Elanco Animal Health Incorporated | ELAN | 2.31% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Apr 11, 2025 | $0.861 | Apr 14, 2025 |
Dec 26, 2024 | $0.254 | Dec 27, 2024 |
Apr 12, 2024 | $0.227 | Apr 15, 2024 |
Dec 21, 2023 | $0.872 | Dec 22, 2023 |
Apr 14, 2023 | $1.035 | Apr 17, 2023 |
Dec 16, 2022 | $0.925 | Dec 19, 2022 |